Litigation Details for AstraZeneca AB v. Aurobindo Pharma Ltd. (D. Del. 2014)
✉ Email this page to a colleague
AstraZeneca AB v. Aurobindo Pharma Ltd. (D. Del. 2014)
| Docket | ⤷ Try a Trial | Date Filed | 2014-05-23 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Gregory Moneta Sleet |
| Jury Demand | Defendant | Referred To | |
| Patents | 6,395,767; 7,951,400; 8,628,799; RE44,186 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AstraZeneca AB v. Aurobindo Pharma Ltd.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for AstraZeneca AB v. Aurobindo Pharma Ltd. (D. Del. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2014-05-23 | 1 | product, prior to expiration of U.S. Patent No. 7,951,400 (“the ’400 patent”). … This is an action for patent infringement arising under the patent laws of the United States, … THE ’400 PATENT 14. On May 31, 2011, the U.S. Patent and Trademark Office …copy of the ’400 patent is attached hereto as Exhibit A. The claims of the ’400 patent are valid and …includes ONGLYZA® together with the’400 patent and U.S. Patent No. RE44,186, which covers the composition | External link to document | |
| 2015-02-18 | 138 | Infringement and Invalidity Contentions for U.S. Patent Nos. 7,951,400 and 8,628,799 by Actavis Laboratories FL… 23 May 2014 1:14-cv-00664-GMS Patent Defendant District Court, D. | External link to document | |
| 2015-04-13 | 155 | Dismissal of Formulation Patent Claims Concerning U.S. Patent No. 7,951,400 Between AstraZeneca and Aurobindo… 23 May 2014 1:14-cv-00664-GMS Patent Defendant District Court, D. | External link to document | |
| 2015-04-13 | 160 | CLAIMS AND COUNTERCLAIMS CONCERNINGU.S. PATENT NOS. 7,951,400 AND 8,628,799 filed by AstraZeneca AB. Signed… 23 May 2014 1:14-cv-00664-GMS Patent Defendant District Court, D. | External link to document | |
| 2015-04-13 | 161 | Stipulation of Dismissal of Formulation Patent Claims U.S. Patent Nos. 7,951,400 AND 8,628,799 filed by AstraZeneca… 23 May 2014 1:14-cv-00664-GMS Patent Defendant District Court, D. | External link to document | |
| 2015-04-14 | 165 | Without Prejudice of Formulation Patent Claims (U.S. Patent No. 7,951,400) Between AstraZeneca and Glenmark… 23 May 2014 1:14-cv-00664-GMS Patent Defendant District Court, D. | External link to document | |
| 2014-09-23 | 17 | than April 18, 2014. Date of Expiration of Patent: 7,951,400 (November 30, 2028).Thirty Month Stay Deadline… Amended Supplemental information for patent cases involving an Abbreviated New Drug Application… 23 May 2014 1:14-cv-00664-GMS Patent Defendant District Court, D. | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
